| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase POSITIVE ION MODE | ASPC-CATP-1 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-CATP-2 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-CATP-3 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-CATP-4 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-CATP-5 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-GATP-1-r002 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-GATP-2 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-GATP-3 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-GATP-4 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase POSITIVE ION MODE | ASPC-GATP-5 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-CATP-1 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-CATP-2 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-CATP-3 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-CATP-4 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-CATP-5 | Treatment:25µl DMSO and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-GATP-1-r002 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-GATP-2 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-GATP-3 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-GATP-4 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
| Reversed phase NEGATIVE ION MODE | ASPC-GATP-5 | Treatment:50µM gemcitabine and 40µM ATP for 72h | counts |
Return to study ST002255 main page
Download data matrix(Functional metabolic molecules were identified as novel therapeutic targets to facilitate gemcitabine treatment against pancreatic cancer (Cells metabolomics with ATP) Reversed phase POSITIVE ION MODE)
Download data matrix(Functional metabolic molecules were identified as novel therapeutic targets to facilitate gemcitabine treatment against pancreatic cancer (Cells metabolomics with ATP) Reversed phase NEGATIVE ION MODE)
- Metabolomics Workbench
|